Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected ...
Some individuals lose their ability to smell as it slowly deteriorates or disappears altogether, significantly impacting ...
Is your childs snoring a sign of something more Understand the risks of sleep-disordered breathing and find expert-backed solutions ...
They can also be used to treat snoring and nasal polyps, noncancerous growths in the nasal passages ... Glaucoma (nerve damage in the eye that can cause loss of vision) Systemic side effects due to ...
Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...
Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...
Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, and quality of life. Epithelial barrier dysfunction and type 2 ...
Detailed price information for Lyra Therapeutics Inc (LYRA-Q) from The Globe and Mail including charting and trades.
AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results